Christopher Kroeger Sells 20,100 Shares of Maplight Therapeutics (NASDAQ:MPLT) Stock

Maplight Therapeutics, Inc. (NASDAQ:MPLT) CEO Christopher Kroeger sold 20,100 shares of the company’s stock in a transaction that occurred on Thursday, May 7th. The shares were sold at an average price of $28.65, for a total transaction of $575,865.00. Following the completion of the transaction, the chief executive officer owned 1,560,720 shares of the company’s stock, valued at $44,714,628. This trade represents a 1.27% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Maplight Therapeutics Trading Up 0.7%

Shares of NASDAQ:MPLT opened at $30.30 on Wednesday. The firm has a market capitalization of $1.29 billion and a price-to-earnings ratio of -0.76. Maplight Therapeutics, Inc. has a 12 month low of $12.24 and a 12 month high of $33.28. The stock’s fifty day moving average is $23.54.

Maplight Therapeutics (NASDAQ:MPLT) last announced its earnings results on Thursday, March 26th. The company reported ($2.47) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.05) by ($1.42). Equities analysts predict that Maplight Therapeutics, Inc. will post -3.96 earnings per share for the current year.

Analyst Upgrades and Downgrades

MPLT has been the subject of several recent research reports. Needham & Company LLC started coverage on Maplight Therapeutics in a research report on Wednesday, April 8th. They set a “buy” rating and a $37.00 price objective for the company. Canaccord Genuity Group initiated coverage on Maplight Therapeutics in a research note on Thursday, March 19th. They issued a “buy” rating and a $35.00 target price on the stock. Weiss Ratings started coverage on Maplight Therapeutics in a research report on Thursday, January 22nd. They set a “sell (e)” rating for the company. HC Wainwright started coverage on shares of Maplight Therapeutics in a research note on Monday, May 4th. They set a “buy” rating and a $45.00 price target for the company. Finally, Wall Street Zen downgraded shares of Maplight Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 21st. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Maplight Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $34.43.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. Strs Ohio bought a new position in Maplight Therapeutics in the fourth quarter valued at approximately $53,000. Blue Owl Capital Holdings LP bought a new stake in shares of Maplight Therapeutics during the 4th quarter worth approximately $5,745,000. Geode Capital Management LLC acquired a new stake in shares of Maplight Therapeutics in the 4th quarter valued at approximately $6,835,000. Seven Grand Managers LLC bought a new position in shares of Maplight Therapeutics in the fourth quarter valued at $1,756,000. Finally, Goldman Sachs Group Inc. bought a new position in shares of Maplight Therapeutics in the fourth quarter valued at $34,026,000.

About Maplight Therapeutics

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.